000141658 001__ 141658
000141658 005__ 20240323120021.0
000141658 0247_ $$2doi$$a10.1186/s12888-019-2377-z
000141658 0247_ $$2pmid$$apmid:31830934
000141658 0247_ $$2pmc$$apmc:PMC6909459
000141658 0247_ $$2altmetric$$aaltmetric:72791893
000141658 037__ $$aDZNE-2020-07982
000141658 041__ $$aEnglish
000141658 082__ $$a610
000141658 1001_ $$0P:(DE-HGF)0$$aTimäus, Charles$$b0$$eCorresponding author
000141658 245__ $$aPharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice.
000141658 260__ $$aHeidelberg$$bSpringer$$c2019
000141658 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2019-12-12
000141658 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2019-12-01
000141658 3367_ $$2DRIVER$$aarticle
000141658 3367_ $$2DataCite$$aOutput Types/Journal article
000141658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711119038_19996
000141658 3367_ $$2BibTeX$$aARTICLE
000141658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141658 3367_ $$00$$2EndNote$$aJournal Article
000141658 520__ $$aThe purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004).Charts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008-2012 with the interval 1996-2004.94% of all inpatients of the interval 2008-2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996-2004, rates of low-potency antipsychotics, tri-/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased.In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation.
000141658 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000141658 542__ $$2Crossref$$i2019-12-01$$uhttp://creativecommons.org/licenses/by/4.0/
000141658 588__ $$aDataset connected to CrossRef, PubMed,
000141658 650_2 $$2MeSH$$aAdult
000141658 650_2 $$2MeSH$$aAnticonvulsants: therapeutic use
000141658 650_2 $$2MeSH$$aAntidepressive Agents: therapeutic use
000141658 650_2 $$2MeSH$$aAntimanic Agents: therapeutic use
000141658 650_2 $$2MeSH$$aAntipsychotic Agents: therapeutic use
000141658 650_2 $$2MeSH$$aBorderline Personality Disorder: drug therapy
000141658 650_2 $$2MeSH$$aBorderline Personality Disorder: epidemiology
000141658 650_2 $$2MeSH$$aBorderline Personality Disorder: psychology
000141658 650_2 $$2MeSH$$aFemale
000141658 650_2 $$2MeSH$$aGermany: epidemiology
000141658 650_2 $$2MeSH$$aHospitalization: trends
000141658 650_2 $$2MeSH$$aHumans
000141658 650_2 $$2MeSH$$aMale
000141658 650_2 $$2MeSH$$aMiddle Aged
000141658 650_2 $$2MeSH$$aNarcotic Antagonists: therapeutic use
000141658 650_2 $$2MeSH$$aPrevalence
000141658 650_2 $$2MeSH$$aPsychotropic Drugs: therapeutic use
000141658 650_2 $$2MeSH$$aRetrospective Studies
000141658 650_2 $$2MeSH$$aTime Factors
000141658 650_2 $$2MeSH$$aYoung Adult
000141658 7001_ $$aMeiser, Miriam$$b1
000141658 7001_ $$aBandelow, Borwin$$b2
000141658 7001_ $$aEngel, Kirsten R$$b3
000141658 7001_ $$aPaschke, Anne M$$b4
000141658 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b5$$udzne
000141658 7001_ $$aWedekind, Dirk$$b6
000141658 77318 $$2Crossref$$3journal-article$$a10.1186/s12888-019-2377-z$$b : Springer Science and Business Media LLC, 2019-12-01$$n1$$p393$$tBMC Psychiatry$$v19$$x1471-244X$$y2019
000141658 773__ $$0PERI:(DE-600)2050438-X$$a10.1186/s12888-019-2377-z$$gVol. 19, no. 1, p. 393$$n1$$p393$$q19:1<393$$tBMC psychiatry$$v19$$x1471-244X$$y2019
000141658 8564_ $$uhttps://pub.dzne.de/record/141658/files/DZNE-2020-07982.pdf$$yOpenAccess
000141658 8564_ $$uhttps://pub.dzne.de/record/141658/files/DZNE-2020-07982.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000141658 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909459
000141658 909CO $$ooai:pub.dzne.de:141658$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000141658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000141658 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000141658 9141_ $$y2019
000141658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000141658 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000141658 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC PSYCHIATRY : 2021$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:20:14Z
000141658 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:20:14Z
000141658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000141658 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000141658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000141658 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000141658 980__ $$ajournal
000141658 980__ $$aVDB
000141658 980__ $$aUNRESTRICTED
000141658 980__ $$aI:(DE-2719)1410006
000141658 9801_ $$aFullTexts
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.4088/JCP.v69n0404$$o10.4088/JCP.v69n0404
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1521/pedi.2010.24.4.412$$o10.1521/pedi.2010.24.4.412
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00406-019-00980-8$$o10.1007/s00406-019-00980-8
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.comppsych.2008.01.007$$o10.1016/j.comppsych.2008.01.007
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1521/pedi.2008.22.4.353$$o10.1521/pedi.2008.22.4.353
000141658 999C5 $$2Crossref$$oJM Stoffers 2012$$y2012
000141658 999C5 $$2Crossref$$o
000141658 999C5 $$2Crossref$$oJM Stoffers 2010$$y2010
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1192/bjp.bp.108.062984$$o10.1192/bjp.bp.108.062984
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s40263-017-0425-0$$o10.1007/s40263-017-0425-0
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/ajp.2006.163.5.827$$o10.1176/ajp.2006.163.5.827
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0171592$$o10.1371/journal.pone.0171592
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00115-011-3462-9$$o10.1007/s00115-011-3462-9
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/ajp.155.12.1733$$o10.1176/ajp.155.12.1733
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/YIC.0000000000000021$$o10.1097/YIC.0000000000000021
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.euroneuro.2015.03.017$$o10.1016/j.euroneuro.2015.03.017
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.4088/JCP.14m09228$$o10.4088/JCP.14m09228
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/appi.ps.201400055$$o10.1176/appi.ps.201400055
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2174/092986711796504682$$o10.2174/092986711796504682
000141658 999C5 $$2Crossref$$oM Jariani 2010$$y2010
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s11920-014-0534-0$$o10.1007/s11920-014-0534-0
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/appi.ajp.2014.13101348$$o10.1176/appi.ajp.2014.13101348
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3109/15622970309167910$$o10.3109/15622970309167910
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/appi.ajp.2018.17091006$$o10.1176/appi.ajp.2018.17091006
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1055/s-2001-15305$$o10.1055/s-2001-15305
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/ajp.142.1.98$$o10.1176/ajp.142.1.98
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1037/a0018095$$o10.1037/a0018095
000141658 999C5 $$2Crossref$$oAS Roth 1996$$y1996
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.4088/JCP.v58n0106e$$o10.4088/JCP.v58n0106e
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/00005053-199603000-00011$$o10.1097/00005053-199603000-00011
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3310/hta11060$$o10.3310/hta11060
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1176/appi.ajp.2008.08020304$$o10.1176/appi.ajp.2008.08020304
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/01.jcp.0000130555.63254.73$$o10.1097/01.jcp.0000130555.63254.73
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/01.ALC.0000139704.88862.01$$o10.1097/01.ALC.0000139704.88862.01
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/alcalc/36.6.544$$o10.1093/alcalc/36.6.544
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.4088/JCP.v69n0511$$o10.4088/JCP.v69n0511
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1192/bjp.bp.110.078105$$o10.1192/bjp.bp.110.078105
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/00004850-199510030-00005$$o10.1097/00004850-199510030-00005
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.4088/JCP.v60n0906$$o10.4088/JCP.v60n0906
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/YIC.0b013e32834d0e50$$o10.1097/YIC.0b013e32834d0e50
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/YIC.0000000000000170$$o10.1097/YIC.0000000000000170
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/JCP.0000000000000232$$o10.1097/JCP.0000000000000232
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/15622970701685224$$o10.1080/15622970701685224
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1037/ccp0000275$$o10.1037/ccp0000275
000141658 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/jamapsychiatry.2016.4287$$o10.1001/jamapsychiatry.2016.4287